E2F1 and metabolic dysfunction-associated steatotic liver disease: In summary, this study provided evidence suggesting that miR-223-3p delivered by ADSC-EVs downregulated the expression of E2F1 to further attenuate the lipid accumulation and fibrosis, which ultimately relieved NAFLD (Figure 8).